Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | SOX18 | P35713 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149656 | 0.84 | DAO (0.73) | DAOGAARAB9AHCAR2 | |
| SCHEMBL1149257 | 0.81 | KDM4E (0.50) | DAOCYP1A2GAARAB9A | |
| SCHEMBL1149736 | 0.78 | DAO (0.64) | DAOGAARAB9AHDAC1HDAC8 | |
| SCHEMBL1149833 | 0.77 | DAO (0.72) | DAOGAARAB9APDPK1 | |
| SCHEMBL1149419 | 0.76 | DAO (0.71) | DAOGAARAB9ACA12 | |
| SCHEMBL1149408 | 0.76 | DAO (0.71) | DAOGAARAB9ADHODH | |
| SCHEMBL27680469 | 0.76 | DAO (0.71) | DAOGAARAB9A | |
| SCHEMBL679780 | 0.76 | DAO (1.00) | DAOGAARAB9ACA12 | |
| SCHEMBL1149716 | 0.76 | DAO (0.71) | DAOGAARAB9APDPK1 | |
| SCHEMBL1149680 | 0.76 | DAO (0.61) | DAOGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7893098-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893098-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7893098-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-7615572-B2 | 4,5-substituted pyrazole-3-carboxylic acids/esters/salts; D-amino acid oxidase (DAAO) inhibitors; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia | SEPRACOR INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615572-B2 | 4,5-substituted pyrazole-3-carboxylic acids/esters/salts; D-amino acid oxidase (DAAO) inhibitors; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia | SEPRACOR INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615572-B2 | 4,5-substituted pyrazole-3-carboxylic acids/esters/salts; D-amino acid oxidase (DAAO) inhibitors; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia | SEPRACOR INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | SEPRACOR INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7488747-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488747-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-7488747-B2 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20050143443-A1 | Pyrrole and pyrazole DAAO inhibitors | SEPRACOR INC. (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092559-A1 | PYRROLE AND PYRAZOLE DAAO INHIBITORS | DDO, DAO, SRR | DAO 2/4885CYP1A2 3265/4885SOX18 2138/4885 |
| US-20100016397-A1 | Pyrrole and Pyrazole DAAO Inhibitors | DDO, DAO, SRR | DAO 2/4885CYP1A2 3265/4885SOX18 2138/4885 |
| US-20050143443-A1 | Pyrrole and pyrazole DAAO inhibitors | DDO, DAO, SRR | DAO 2/4885CYP1A2 3265/4885SOX18 2138/4885 |
| US-20090170916-A1 | Pyrrole and Pyrazole DAAO Inhibitors | DDO, DAO, SRR | DAO 2/4885CYP1A2 3265/4885SOX18 2138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.